drugset / Trial / NCT05348122
A Study of TG103 Injection in Type 2 Diabetes Subjects
RandomizedParallel-groupSingle-blindTreatment
Summary
The primary objective of this trial is to evaluate the efficacy of different doses and frequencies of administration of TG103 injection in the treatment of type 2 diabetes.
Timeline
- Start
- 2022-06-15
- Primary completion
- 2023-11-01
- Completion
- 2023-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dulaglutide | Peptide | — | Subcutaneous |
| Subject | TG103 | Protein / enzyme biologic | 7.5 mg | Subcutaneous |
| Subject | TG103 | Protein / enzyme biologic | 15 mg | Subcutaneous |
| Subject | TG103 | Protein / enzyme biologic | 22.5 mg | Subcutaneous |